Author

E. Labanca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:variant calling· 1

Frequent Co-Authors

J. Yang· 2 shared A. Futreal· 1 shared A. J. Todd· 1 shared A. M. Aparicio· 1 shared A. M. Chinnaiyan· 1 shared A. Parolia· 1 shared C. Cheng· 1 shared C. J. Logothetis· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Yang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

J. C.-Y. Tien, Y. Chang, Y. Zhang, J. Chou, Y. Cheng, X. Wang, J. Yang, R. Mannan, P. Shah, X.-M. Wang, A. J. Todd, S. Eyunni, C. Cheng, R. J. Rebernick, L. Xiao, , A. M. Chinnaiyan

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

bioRxiv · Mar 20, 2024Cancer Biology

Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX)

N. Anselmino, E. Labanca, X. Song, J. Yang, P. D. Shepherd, J. Dong, R. Kundra, N. Schultz, J. Zhang, J. C. Araujo, A. M. Aparicio, S. K. Subudhi, P. G. Corn, L. L. Pisters, J. F. Ward, , N. M. Navone

The paper characterizes the genomic and transcriptomic landscape of MDA PCa PDX models and develops an organoid platform to study prostate cancer heterogeneity and resistance.

bioRxiv · Jul 21, 2022 · PreprintCancer Biology